Literature DB >> 22227015

Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells.

Jim Jinn-Chyuan Sheu1, Bin Guan2, Fuu-Jen Tsai3, Erin Yi-Ting Hsiao3, Chih-Mei Chen3, Raquel Seruca4, Tian-Li Wang2, Ie-Ming Shih5.   

Abstract

Although the oncogenic functions of activating BRAF mutations have been clearly demonstrated in human cancer, their roles in nontransformed epithelial cells remain largely unclear. Investigating the cellular response to the expression of mutant BRAF in nontransformed epithelial cells is fundamental to the understanding of the roles of BRAF in cancer pathogenesis. In this study, we used two nontransformed cyst108 and RK3E epithelial cell lines as models in which to compare the phenotypes of cells expressing BRAF(WT) and BRAF(V600E). We found that transfection of the BRAF(V600E), but not the BRAF(WT), expression vector suppressed cellular proliferation and induced apoptosis in both cell types. BRAF(V600E) generated reactive oxygen species, induced DNA double-strand breaks, and caused subsequent DNA damage response as evidenced by an increased number of pCHK2 and γH2AX nuclear foci as well as the up-regulation of pCHK2, p53, and p21. Because BRAF and KRAS (alias Ki-ras) mutations have been correlated with GLUT1 up-regulation, which encodes glucose transporter-1, we demonstrated here that expression of BRAF(V600E), but not BRAF(WT), was sufficient to up-regulate GLUT1. Taken together, our findings provide new insights into mutant BRAF-induced oncogenic stress that is manifested by DNA damage and growth arrest by activating the pCHK2-p53-p21 pathway in nontransformed cells, while it also confers tumor-promoting phenotypes such as the up-regulation of GLUT1 that contributes to enhanced glucose metabolism that characterizes tumor cells. Copyright Â
© 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22227015      PMCID: PMC4429179          DOI: 10.1016/j.ajpath.2011.11.026

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  57 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  A simple technique for quantitation of low levels of DNA damage in individual cells.

Authors:  N P Singh; M T McCoy; R R Tice; E L Schneider
Journal:  Exp Cell Res       Date:  1988-03       Impact factor: 3.905

3.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

4.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

5.  DRO1, a gene down-regulated by oncogenes, mediates growth inhibition in colon and pancreatic cancer cells.

Authors:  Guido T Bommer; Claudia Jäger; Eva-Maria Dürr; Sebastian Baehs; Sören T Eichhorst; Thomas Brabletz; Gang Hu; Thomas Fröhlich; Georg Arnold; Dagmar C Kress; Burkhard Göke; Eric R Fearon; Frank T Kolligs
Journal:  J Biol Chem       Date:  2004-11-24       Impact factor: 5.157

6.  Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.

Authors:  Gudrun Pohl; Chung-Liang Ho; Robert J Kurman; Robert Bristow; Tian-Li Wang; Ie-Ming Shih
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

7.  Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features.

Authors:  P C Huettner; D S Weinberg; J M Lage
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

8.  Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.

Authors:  Chih-Yi Hsu; Robert Bristow; Moon Seok Cha; Brant G Wang; Chung-Liang Ho; Robert J Kurman; Tian-Li Wang; Ie-Ming Shih
Journal:  Clin Cancer Res       Date:  2004-10-01       Impact factor: 12.531

9.  ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation.

Authors:  Frank T Kolligs; Marvin T Nieman; Ira Winer; Gang Hu; David Van Mater; Ying Feng; Ian M Smith; Rong Wu; Yali Zhai; Kathleen R Cho; Eric R Fearon
Journal:  Cancer Cell       Date:  2002-03       Impact factor: 31.743

10.  A dimerization-dependent mechanism drives RAF catalytic activation.

Authors:  Thanashan Rajakulendran; Malha Sahmi; Martin Lefrançois; Frank Sicheri; Marc Therrien
Journal:  Nature       Date:  2009-09-02       Impact factor: 49.962

View more
  11 in total

1.  BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.

Authors:  Felix Zeppernick; Laura Ardighieri; Charlotte G Hannibal; Russell Vang; Jette Junge; Susanne K Kjaer; Rugang Zhang; Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2014-12       Impact factor: 6.394

Review 2.  The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2016-04       Impact factor: 4.307

3.  Membrane Bound Peroxiredoxin-1 Serves as a Biomarker for In Vivo Detection of Sessile Serrated Adenomas.

Authors:  Sangeeta Jaiswal; Bishnu Joshi; Jing Chen; Fa Wang; Michael K Dame; Jason R Spence; Gina M Newsome; Erica L Katz; Yatrik M Shah; Sadeesh K Ramakrishnan; Gaoming Li; Miki Lee; Henry D Appelman; Rork Kuick; Thomas D Wang
Journal:  Antioxid Redox Signal       Date:  2021-12-21       Impact factor: 8.401

4.  Oncogenic BRAF(V600E) Induces Clastogenesis and UVB Hypersensitivity.

Authors:  Dennis A Simpson; Nathalay Lemonie; David S Morgan; Shobhan Gaddameedhi; William K Kaufmann
Journal:  Cancers (Basel)       Date:  2015-06-17       Impact factor: 6.639

5.  Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876.

Authors:  Holger Siebeneicher; Arwed Cleve; Hartmut Rehwinkel; Roland Neuhaus; Iring Heisler; Thomas Müller; Marcus Bauser; Bernd Buchmann
Journal:  ChemMedChem       Date:  2016-08-23       Impact factor: 3.466

6.  Conformational Studies of Glucose Transporter 1 (GLUT1) as an Anticancer Drug Target.

Authors:  Suliman Almahmoud; Xiaofang Wang; Jonathan L Vennerstrom; Haizhen A Zhong
Journal:  Molecules       Date:  2019-06-07       Impact factor: 4.411

7.  Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study.

Authors:  Naoto Mukada; Masahiko Tosaka; Nozomi Matsumura; Rei Yamaguchi; Masanori Aihara; Koji Isoda; Tetsuya Higuchi; Yoshito Tsushima; Hideaki Yokoo; Yuhei Yoshimoto
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

8.  Functional and genetic determinants of mutation rate variability in regulatory elements of cancer genomes.

Authors:  Christian A Lee; Diala Abd-Rabbo; Jüri Reimand
Journal:  Genome Biol       Date:  2021-05-03       Impact factor: 13.583

9.  Potential clinical implications of BRAF mutations in histiocytic proliferations.

Authors:  Anna-Maria Bubolz; Stephanie E Weissinger; Albrecht Stenzinger; Annette Arndt; Konrad Steinestel; Silke Brüderlein; Holger Cario; Anneli Lubatschofski; Claudia Welke; Ioannis Anagnostopoulos; Thomas F E Barth; Ambros J Beer; Peter Möller; Martin Gottstein; Andreas Viardot; Jochen K Lennerz
Journal:  Oncotarget       Date:  2014-06-30

10.  MLL1 is essential for the senescence-associated secretory phenotype.

Authors:  Brian C Capell; Adam M Drake; Jiajun Zhu; Parisha P Shah; Zhixun Dou; Jean Dorsey; Daniel F Simola; Greg Donahue; Morgan Sammons; Taranjit Singh Rai; Christopher Natale; Todd W Ridky; Peter D Adams; Shelley L Berger
Journal:  Genes Dev       Date:  2016-02-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.